Microtubule stabilizing agents: Their molecular signaling consequences and the potential for enhancement by drug combination

Cancer Treatment Reviews

Volumn 32, Issue 3, 2006, Pages 166-179

  Bergstralh, Daniel T ^a   Ting, Jenny P Y ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Akt; COX 2; MEK; Microtubules; NF B; Spindle checkpoint; Taxanes

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANTHRACYCLINE DERIVATIVE; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CELECOXIB; CISPLATIN; CORTICOSTEROID; DISCODERMOLIDE; DOCETAXEL; ELEUTHEROBIN; EPOTHILONE DERIVATIVE; FLAVOPIRIDOL; GEMCITABINE; GLYCOPROTEIN P; I KAPPA B KINASE INHIBITOR; LAULIMALIDE; MICROTUBULE PROTEIN; MICROTUBULE STABILIZING AGENT; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PACLITAXEL; PURVALANOL A; TAXANE DERIVATIVE; TILMACOXIB; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SOLUBILITY; HEART DISEASE; HUMAN; IMMUNE DEFICIENCY; MICROTUBULE ASSEMBLY; MITOSIS SPINDLE; MOLECULAR MECHANICS; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; UNSPECIFIED SIDE EFFECT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ALKANES; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBAMATES; CYCLOOXYGENASE 2; DITERPENES; EPOTHILONES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERLEUKIN-1; INTERLEUKIN-8; LACTONES; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MATURATION-PROMOTING FACTOR; MICROTUBULE-ASSOCIATED PROTEINS; MICROTUBULES; NEOPLASM PROTEINS; NEOPLASMS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; PYRONES; SIGNAL TRANSDUCTION; TAXOIDS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33645937652     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.01.004     Document Type: Review

References (193)

1. Schiff P.B., Fant J., and Horwitz S.B. Promotion of microtubule assembly in vitro by Taxol. Nature 277 5698 (1979) 665-667
2. Schiff P.B., and Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77 3 (1980) 1561-1565
3. Ojima I., Chakravarty S., Inoue T., et al. A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc Natl Acad Sci USA 96 8 (1999) 4256-4261
4. Rao S., He L., Chakravarty S., Ojima I., Orr G.A., and Horwitz S.B. Characterization of the Taxol binding site on the microtubule. Identification of Arg(282) in β-tubulin as the site of photoincorporation of a 7-benzophenone analogue of Taxol. J Biol Chem 274 53 (1999) 37990-37994
5. Jordan M.A., Wendell K., Gardiner S., Derry W.B., Copp H., and Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56 4 (1996) 816-825
6. Yvon A.M., Wadsworth P., and Jordan M.A. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 10 4 (1999) 947-959
7. Blagosklonny M.V., and Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 83 2 (1999) 151-156
8. Rowinsky E.K. Taxane analogues: distinguishing royal robes from the "Emperor's New Clothes. Clin Cancer Res 8 9 (2002) 2759-2763
9. Rowinsky E.K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48 (1997) 353-374
10. Wani M.C., Taylor H.L., Wall M.E., Coggon P., and McPhail A.T. Plant antitumor agents. VI. Isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93 9 (1971) 2325-2327
11. Chan O.T., and Yang L.X. The immunological effects of taxanes. Cancer Immunol Immunother 49 4-5 (2000) 181-185
12. Gerth K., Bedorf N., Hofle G., Irschik H., and Reichenbach H. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) 49 6 (1996) 560-563
13. Bollag D.M., McQueney P.A., Zhu J., et al. Epothilones, a new class of microtubule stabilizing agents with a Taxol-like mechanism of action. Cancer Res 55 11 (1995) 2325-2333
14. Bergstralh D.T., Taxman D.J., Chou T.C., Danishefsky S.J., and Ting J.P. A comparison of signaling activities induced by Taxol and desoxyepothilone B. J Chemother 16 6 (2004) 563-576
15. Mani S., Macapinlac Jr. M., Goel S., et al. The clinical development of new mitotic inhibitors that stabilize the microtubule. Anticancer Drugs 15 6 (2004) 553-558
16. Goodin S., Kane M.P., and Rubin E.H. Epothilones: mechanism of action and biologic activity. J Clin Oncol 22 10 (2004) 2015-2025
17. Mooberry S.L., Tien G., Hernandez A.H., Plubrukarn A., and Davidson B.S. Laulimalide and isolaulimalide, new paclitaxel-like microtubule stabilizing agents. Cancer Res 59 3 (1999) 653-660
18. Lindel T., Jensen P.R., Fenical W., et al. Eleutherobin, a new cytotoxin that mimics paclitaxel (Taxol) by stabilizing microtubules. J Am Chem Soc 119 37 (1997) 8744-8745
19. Long B.H., Carboni J.M., Wasserman A.J., et al. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol). Cancer Res 58 6 (1998) 1111-1115
20. Longley R.E., Caddigan D., Harmody D., Gunasekera M., and Gunasekera S.P. Discodermolide - a new, marine-derived immunosuppressive compound. I. In vitro studies. Transplantation 52 4 (1991) 650-656
21. Longley R.E., Caddigan D., Harmody D., Gunasekera M., and Gunasekera S.P. Discodermolide - a new, marine-derived immunosuppressive compound. II. In vivo studies. Transplantation 52 4 (1991) 656-661
22. Gunasekera S.P., Paul G.K., Longley R.E., Isbrucker R.A., and Pomponi S.A. Five new discodermolide analogues from the marine sponge Discodermia species. J Nat Prod 65 11 (2002) 1643-1648
23. ter Haar E., Kowalski R.J., Hamel E., et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than Taxol. Biochemistry 35 1 (1996) 243-250
24. Kowalski R.J., Giannakakou P., Gunasekera S.P., Longley R.E., Day B.W., and Hamel E. The microtubule stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol 52 4 (1997) 613-622
25. Martello L.A., LaMarche M.J., He L., Beauchamp T.J., Smith A.B., and Horwitz S.B. The relationship between Taxol and (+)-discodermolide: synthetic analogs and modeling studies. Chem Biol 8 9 (2001) 843-855
26. Martello L.A., McDaid H.M., Regl D.L., et al. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin Cancer Res 6 5 (2000) 1978-1987
27. Klein L.E., Freeze B.S., Smith III A.B., and Horwitz S.B. The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence. Cell Cycle 4 3 (2005) 501-507
28. Mita A., Lockhart A.C., Chen T.-L., et al. A phase I pharmacokinetic (PK) trial of XAA296A (Discodermolide) administered every 3 weeks to adult patients with advanced solid malignancies (ABSTRACT). J Clin Oncol 22 14S (2004) 2025
29. Makin G., and Dive C. Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy?. Breast Cancer Res 3 3 (2001) 150-153
30. Rigas J.R. Taxane-platinum combinations in advanced non-small cell lung cancer: a review. Oncologist 9 Suppl. 2 (2004) 16-23
31. Kosmidis P., Mylonakis N., Nicolaides C., et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 20 17 (2002) 3578-3585
32. Athanasiadis A., Roussos G., Papakostoulis T., Athanasiadou D.C., and Stathopoulos G.P. Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase I study. Cancer Chemother Pharmacol 56 6 (2005) 653-658
33. Nabholtz J.M. Docetaxel-anthracycline combinations in metastatic breast cancer. Breast Cancer Res Treat 79 Suppl. 1 (2003) S3-S9
34. Ho Y.P., Au-Yeung S.C., and To K.K. Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med Res Rev 23 5 (2003) 633-655
35. Manegold C., Zatloukal P., Krejcy K., and Blatter J. Gemcitabine in non-small cell lung cancer NSCLC. Invest New Drugs 18 1 (2000) 29-42
36. Sandler A., and Ettinger D.S. Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. Oncologist 4 3 (1999) 241-251
37. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57 7 (1999) 727-741
38. Greulich H., and Erikson R.L. An analysis of Mek1 signaling in cell proliferation and transformation. J Biol Chem 273 21 (1998) 13280-13288
39. Tibbles L.A., and Woodgett J.R. The stress-activated protein kinase pathways. Cell Mol Life Sci 55 10 (1999) 1230-1254
40. Lee L.F., Li G., Templeton D.J., and Ting J.P. Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem 273 43 (1998) 28253-282560
41. Seidman R., Gitelman I., Sagi O., Horwitz S.B., and Wolfson M. The role of ERK 1/2 and p38 MAP-kinase pathways in Taxol-induced apoptosis in human ovarian carcinoma cells. Exp Cell Res 268 1 (2001) 84-92
42. Sebolt-Leopold J.S. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19 56 (2000) 6594-6599
43. Sebolt-Leopold J.S., and Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4 12 (2004) 937-947
44. MacKeigan J.P., Collins T.S., and Ting J.P. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 275 50 (2000) 38953-38956
45. McDaid H.M., and Horwitz S.B. Selective potentiation of paclitaxel (Taxol)-induced cell death by mitogen-activated protein kinase inhibition in human cancer cell lines. Mol Pharmacol 60 2 (2001) 290-301
46. Yu C., Wang S., Dent P., and Grant S. Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase/mitogen-activated protein kinase pathway. Mol Pharmacol 60 1 (2001) 143-154
47. Yacoub A., Han S.I., Caron R., et al. Sequence dependent exposure of mammary carcinoma cells to Taxotere and the MEK1/2 inhibitor U0126 causes enhanced cell killing in vitro. Cancer Biol Ther 2 6 (2003) 670-676
48. Allen L.F., Sebolt-Leopold J., and Meyer M.B. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 30 5 Suppl. 16 (2003) 105-116
49. Sebolt-Leopold J.S., Dudley D.T., Herrera R., et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5 7 (1999) 810-816
50. McDaid H.M., Lopez-Barcons L., Grossman A., et al. Enhancement of the therapeutic efficacy of Taxol by the mitogen-activated protein kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res 65 7 (2005) 2854-2860
51. Lorusso P.M., Adjei A.A., Varterasian M., et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23 23 (2005) 5281-5293
52. Rinehart J., Adjei A.A., Lorusso P.M., et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22 22 (2004) 4456-4462
53. Taxman D.J., MacKeigan J.P., Clements C., Bergstralh D.T., and Ting J.P. Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogen-activated protein/extracellular signal-regulated kinase inhibitor. Cancer Res 63 16 (2003) 5095-5104
54. MacKeigan J.P., Clements C.M., Lich J.D., Pope R.M., Hod Y., and Ting J.P. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIα. Cancer Res 63 20 (2003) 6928-6934
55. Yang C.P., and Horwitz S.B. Taxol mediates serine phosphorylation of the 66 kDa Shc isoform. Cancer Res 60 18 (2000) 5171-5178
56. Brantley-Finley C., Lyle C.S., Du L., et al. The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide. Biochem Pharmacol 66 3 (2003) 459-469
57. Chung E., and Chen R.H. Phosphorylation of Cdc20 is required for its inhibition by the spindle checkpoint. Nat Cell Biol 5 8 (2003) 748-753
58. Kops G.J., Weaver B.A., and Cleveland D.W. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5 10 (2005) 773-785
59. Bharadwaj R., and Yu H. The spindle checkpoint, aneuploidy, and cancer. Oncogene 23 11 (2004) 2016-2027
60. Sorger P.K., Dobles M., Tournebize R., and Hyman A.A. Coupling cell division and cell death to microtubule dynamics. Curr Opin Cell Biol 9 6 (1997) 807-814
61. Waters J.C., Chen R.H., Murray A.W., and Salmon E.D. Localization of Mad2 to kinetochores depends on microtubule attachment, not tension. J Cell Biol 141 5 (1998) 1181-1191
62. Martinez-Exposito M.J., Kaplan K.B., Copeland J., and Sorger P.K. Retention of the BUB3 checkpoint protein on lagging chromosomes. Proc Natl Acad Sci USA 96 15 (1999) 8493-8498
63. Huang T.S., Shu C.H., Chao Y., Chen S.N., and Chen L.L. Activation of MAD 2 checkprotein and persistence of cyclin B1/CDC 2 activity associate with paclitaxel-induced apoptosis in human nasopharyngeal carcinoma cells. Apoptosis 5 3 (2000) 235-241
64. Blajeski A.L., Kottke T.J., and Kaufmann S.H. A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines. Exp Cell Res 270 2 (2001) 277-288
65. Chen J.G., Yang C.P., Cammer M., and Horwitz S.B. Gene expression and mitotic exit induced by microtubule stabilizing drugs. Cancer Res 63 22 (2003) 7891-7899
66. Tao W., South V.J., Zhang Y., et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 8 1 (2005) 49-59
67. Anand S., Penrhyn-Lowe S., and Venkitaraman A.R. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3 1 (2003) 51-62
68. Pages G., Lenormand P., L'Allemain G., Chambard J.C., Meloche S., and Pouyssegur J. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci USA 90 18 (1993) 8319-8323
69. Cowley S., Paterson H., Kemp P., and Marshall C.J. Activation of MAP kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77 6 (1994) 841-852
70. Mansour S.J., Matten W.T., Hermann A.S., et al. Transformation of mammalian cells by constitutively active MAP kinase. Science 265 5174 (1994) 966-970
71. Roovers K., and Assoian R.K. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays 22 9 (2000) 818-826
72. Maller J.L., Schwab M.S., Gross S.D., Taieb F.E., Roberts B.T., and Tunquist B.J. The mechanism of CSF arrest in vertebrate oocytes. Mol Cell Endocrinol 187 1-2 (2002) 173-178
73. Posada J., Yew N., Ahn N.G., Vande Woude G.F., and Cooper J.A. Mos stimulates MAP kinase in Xenopus oocytes and activates a MAP kinase in vitro. Mol Cell Biol 13 4 (1993) 2546-2553
74. Shapiro P.S., Vaisberg E., Hunt A.J., et al. Activation of the MKK/ERK pathway during somatic cell mitosis: direct interactions of active ERK with kinetochores and regulation of the mitotic 3F3/2 phosphoantigen. J Cell Biol 142 6 (1998) 1533-1545
75. Guadagno T.M., and Ferrell Jr. J.E. Requirement for MAPK activation for normal mitotic progression in Xenopus egg extracts. Science 282 5392 (1998) 1312-1315
76. Liu X., Yan S., Zhou T., Terada Y., and Erikson R.L. The MAP kinase pathway is required for entry into mitosis and cell survival. Oncogene 23 3 (2004) 763-776
77. Seger R., and Krebs E.G. The MAPK signaling cascade. Faseb J 9 9 (1995) 726-735
78. Crews C.M., Alessandrini A., and Erikson R.L. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 258 5081 (1992) 478-480
79. Seger R., Seger D., Lozeman F.J., et al. Human T-cell mitogen-activated protein kinases are related to yeast signal transduction kinases. J Biol Chem 267 36 (1992) 25628-25631
80. Fang G., Chang B.S., Kim C.N., Perkins C., Thompson C.B., and Bhalla K.N. "Loop" domain is necessary for Taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting Taxol-induced cytosolic accumulation of cytochrome c and apoptosis. Cancer Res 58 15 (1998) 3202-3208
81. Srivastava R.K., Mi Q.S., Hardwick J.M., and Longo D.L. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA 96 7 (1999) 3775-3780
82. Wang H.G., Miyashita T., Takayama S., et al. Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. Oncogene 9 9 (1994) 2751-2756
83. Blagosklonny M.V., Giannakakou P., el-Deiry W.S., et al. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 57 1 (1997) 130-135
84. Lee M., Koh W.S., and Han S.S. Down-regulation of Raf-1 kinase is associated with paclitaxel resistance in human breast cancer MCF-7/Adr cells. Cancer Lett 193 1 (2003) 57-64
85. Cheung H.W., Ling M.T., Tsao S.W., Wong Y.C., and Wang X. Id-1-induced Raf/MEK pathway activation is essential for its protective role against Taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis 25 6 (2004) 881-887
86. Yue J., and Ferrell Jr. J.E. Mos mediates the mitotic activation of p42 MAPK in Xenopus egg extracts. Curr Biol 14 17 (2004) 1581-1586
87. Ling Y.H., Yang Y., Tornos C., Singh B., and Perez-Soler R. Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells. Cancer Res 58 16 (1998) 3633-3640
88. Blagosklonny M.V., Chuman Y., Bergan R.C., and Fojo T. Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells. Leukemia 13 7 (1999) 1028-1036
89. Minshull J., Sun H., Tonks N.K., and Murray A.W. A MAP kinase-dependent spindle assembly checkpoint in Xenopus egg extracts. Cell 79 3 (1994) 475-486
90. Takenaka K., Gotoh Y., and Nishida E. MAP kinase is required for the spindle assembly checkpoint but is dispensable for the normal M phase entry and exit in Xenopus egg cell cycle extracts. J Cell Biol 136 5 (1997) 1091-1097
91. Wang X.M., Zhai Y., and Ferrell Jr. J.E. A role for mitogen-activated protein kinase in the spindle assembly checkpoint in XTC cells. J Cell Biol 137 2 (1997) 433-443
92. Gachet Y., Tournier S., Millar J.B., and Hyams J.S. A MAP kinase-dependent actin checkpoint ensures proper spindle orientation in fission yeast. Nature 412 6844 (2001) 352-355
93. Johnson V.L., Scott M.I., Holt S.V., Hussein D., and Taylor S.S. Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression. J Cell Sci 117 Pt 8 (2004) 1577-1589
94. Wang X.M., Yew N., Peloquin J.G., Vande Woude G.F., and Borisy G.G. Mos oncogene product associates with kinetochores in mammalian somatic cells and disrupts mitotic progression. Proc Natl Acad Sci USA 91 18 (1994) 8329-8333
95. Taylor S.S., and McKeon F. Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage. Cell 89 5 (1997) 727-735
96. Reszka A.A., Seger R., Diltz C.D., Krebs E.G., and Fischer E.H. Association of mitogen-activated protein kinase with the microtubule cytoskeleton. Proc Natl Acad Sci USA 92 19 (1995) 8881-8885
97. Schwab M.S., Roberts B.T., Gross S.D., et al. Bub1 is activated by the protein kinase p90(Rsk) during Xenopus oocyte maturation. Curr Biol 11 3 (2001) 141-150
98. Tunquist B.J., Schwab M.S., Chen L.G., and Maller J.L. The spindle checkpoint kinase bub1 and cyclin e/cdk2 both contribute to the establishment of meiotic metaphase arrest by cytostatic factor. Curr Biol 12 12 (2002) 1027-1033
99. Ohi R., and Gould K.L. Regulating the onset of mitosis. Curr Opin Cell Biol 11 2 (1999) 267-273
100. Tan A.L., Rida P.C., and Surana U. Essential tension and constructive destruction: the spindle checkpoint and its regulatory links with mitotic exit. Biochem J 386 Pt 1 (2005) 1-13
101. Ling Y.H., Consoli U., Tornos C., Andreeff M., and Perez-Soler R. Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with Taxol. Int J Cancer 75 6 (1998) 925-932
102. Bible K.C., and Kaufmann S.H. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 57 16 (1997) 3375-3380
103. Yu D., Jing T., Liu B., et al. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 2 5 (1998) 581-591
104. Motwani M., Delohery T.M., and Schwartz G.K. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 5 7 (1999) 1876-1883
105. O'Connor D.S., Wall N.R., Porter A.C., and Altieri D.C. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2 1 (2002) 43-54
106. Pennati M., Campbell A.J., Curto M., et al. Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther 4 9 (2005) 1328-1337
107. Shapiro G.I. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 10 12 Pt 2 (2004) 4270s-4275s
108. Senderowicz A.M. Small-molecule cyclin-dependent kinase modulators. Oncogene 22 42 (2003) 6609-6620
109. Abrieu A., Doree M., and Fisher D. The interplay between cyclin-B-Cdc2 kinase (MPF) and MAP kinase during maturation of oocytes. J Cell Sci 114 Pt. 2 (2001) 257-267
110. O'Connor D.S., Grossman D., Plescia J., et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 97 24 (2000) 13103-13107
111. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3 8 (1997) 917-921
112. Li F., Ambrosini G., Chu E.Y., et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396 6711 (1998) 580-584
113. Fortugno P., Wall N.R., Giodini A., et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 115 Pt 3 (2002) 575-585
114. Skoufias D.A., Mollinari C., Lacroix F.B., and Margolis R.L. Human survivin is a kinetochore-associated passenger protein. J Cell Biol 151 7 (2000) 1575-1582
115. Adams R.R., Carmena M., and Earnshaw W.C. Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol 11 2 (2001) 49-54
116. Lens S.M., Wolthuis R.M., Klompmaker R., et al. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. Embo J 22 12 (2003) 2934-2947
117. Ditchfield C., Johnson V.L., Tighe A., et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 161 2 (2003) 267-280
118. Hauf S., Cole R.W., LaTerra S., et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 161 2 (2003) 281-294
119. Lens S.M., and Medema R.H. The survivin/Aurora B complex: its role in coordinating tension and attachment. Cell Cycle 2 6 (2003) 507-510
120. Carvalho A., Carmena M., Sambade C., Earnshaw W.C., and Wheatley S.P. Survivin is required for stable checkpoint activation in Taxol-treated HeLa cells. J Cell Sci 116 Pt 14 (2003) 2987-2998
121. Zhou J., O'Brate A., Zelnak A., and Giannakakou P. Survivin deregulation in β-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to Taxol. Cancer Res 64 23 (2004) 8708-8714
122. Fujie Y., Yamamoto H., Ngan C.Y., et al. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn J Clin Oncol 35 8 (2005) 453-463
123. Zaffaroni N., Pennati M., Colella G., et al. Expression of the anti-apoptotic gene survivin correlates with Taxol resistance in human ovarian cancer. Cell Mol Life Sci 59 8 (2002) 1406-1412
124. Zaffaroni N., Pennati M., and Daidone M.G. Survivin as a target for new anticancer interventions. J Cell Mol Med 9 2 (2005) 360-372
125. Eastman A. Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J Cell Biochem 91 2 (2004) 223-231
126. Woods C.M., Zhu J., McQueney P.A., Bollag D., and Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1 5 (1995) 506-526
127. Weinstein J.N., Myers T.G., O'Connor P.M., et al. An information-intensive approach to the molecular pharmacology of cancer. Science 275 5298 (1997) 343-349
128. Debernardis D., Sire E.G., De Feudis P., et al. p53 Status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 57 5 (1997) 870-874
129. Takahashi M., Kigawa J., Minagawa Y., et al. Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells. Eur J Cancer 36 14 (2000) 1863-1868
130. Osaki S., Nakanishi Y., Takayama K., Pei X.H., Ueno H., and Hara N. Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells. Cancer Gene Ther 7 2 (2000) 300-307
131. Sezgin C., Karabulut B., Uslu R., et al. Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer. J Chemother 17 1 (2005) 96-103
132. Reinecke P., Kalinski T., Mahotka C., et al. Paclitaxel/Taxol sensitivity in human renal cell carcinoma is not determined by the p53 status. Cancer Lett 222 2 (2005) 165-171
133. Blagosklonny M.V., Schulte T.W., Nguyen P., Mimnaugh E.G., Trepel J., and Neckers L. Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res 55 20 (1995) 4623-4626
134. Giannakakou P., Robey R., Fojo T., and Blagosklonny M.V. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 20 29 (2001) 3806-3813
135. Giannakakou P., Nakano M., Nicolaou K.C., et al. Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci USA 99 16 (2002) 10855-10860
136. Lanni J.S., and Jacks T. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 18 2 (1998) 1055-1064
137. Di Leonardo A., Khan S.H., Linke S.P., Greco V., Seidita G., and Wahl G.M. DNA replication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res 57 6 (1997) 1013-1019
138. Barboule N., Chadebech P., Baldin V., Vidal S., and Valette A. Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line. Oncogene 15 23 (1997) 2867-2875
139. Li W., Fan J., Banerjee D., and Bertino J.R. Overexpression of p21(waf1) decreases G2-M arrest and apoptosis induced by paclitaxel in human sarcoma cells lacking both p53 and functional Rb protein. Mol Pharmacol 55 6 (1999) 1088-1093
140. Baldwin Jr. A.S. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 14 (1996) 649-683
141. Dong Q.G., Sclabas G.M., Fujioka S., et al. The function of multiple IκB: NF-κB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 21 42 (2002) 6510-6519
142. Huang Y., and Fan W. IκB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines. Mol Pharmacol 61 1 (2002) 105-113
143. Uzzo R.G., Leavis P., Hatch W., et al. Zinc inhibits nuclear factor-κB activation and sensitizes prostate cancer cells to cytotoxic agents. Clin Cancer Res 8 11 (2002) 3579-3583
144. Mabuchi S., Ohmichi M., Nishio Y., et al. Inhibition of NF-κB increases the efficacy of cisplatin in vitro and in vivo ovarian cancer models. J Biol Chem 279 22 (2004) 23477-23485
145. Patel N.M., Nozaki S., Shortle N.H., et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide. Oncogene 19 36 (2000) 4159-4169
146. Pande V., and Ramos M.J. NF-κB in human disease: current inhibitors and prospects for de novo structure based design of inhibitors. Curr Med Chem 12 3 (2005) 357-374
147. Karin M., Yamamoto Y., and Wang Q.M. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 3 1 (2004) 17-26
148. Mabuchi S., Ohmichi M., Nishio Y., et al. Inhibition of inhibitor of nuclear factor-κB phosphorylation increases the efficacy of paclitaxel in vitro and in vivo ovarian cancer models. Clin Cancer Res 10 22 (2004) 7645-7654
149. Fitzpatrick F.A., and Wheeler R. The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents. Int Immunopharmacol 3 13-14 (2003) 1699-1714
150. Huang Y., Johnson K.R., Norris J.S., and Fan W. Nuclear factor-κB/IκB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 60 16 (2000) 4426-4432
151. LaCasse E.C., Baird S., Korneluk R.G., and MacKenzie A.E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17 25 (1998) 3247-3259
152. Salvesen G.S., and Duckett C.S. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 3 6 (2002) 401-410
153. Mukaida N. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol 284 4 (2003) L566-L577
154. Ishikawa F., and Miyazaki S. New biodefense strategies by neutrophils. Arch Immunol Ther Exp (Warsz) 53 3 (2005) 226-233
155. Collins T.S., Lee L.F., and Ting J.P. Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-κB- and AP-1-dependent mechanism. Cancer Immunol Immunother 49 2 (2000) 78-84
156. Lee L.F., Schuerer-Maly C.C., Lofquist A.K., et al. Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer. Cancer Res 56 6 (1996) 1303-1308
157. Duan Z., Feller A.J., Penson R.T., Chabner B.A., and Seiden M.V. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 5 11 (1999) 3445-3453
158. Penson R.T., Kronish K., Duan Z., et al. Cytokines IL-1β, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFα in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 10 1 (2000) 33-41
159. Mayerhofer K., Bodner K., Bodner-Adler B., et al. Interleukin-8 serum level shift in patients with ovarian carcinoma undergoing paclitaxel-containing chemotherapy. Cancer 91 2 (2001) 388-393
160. Pusztai L., Mendoza T.R., Reuben J.M., et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25 3 (2004) 94-102
161. Lee L.F., Haskill J.S., Mukaida N., Matsushima K., and Ting J.P. Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter. Mol Cell Biol 17 9 (1997) 5097-5105
162. Lee L.F., Hellendall R.P., Wang Y., et al. IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol 164 5 (2000) 2769-2775
163. O'Brien Jr. J.M., Wewers M.D., Moore S.A., and Allen J.N. Taxol and colchicine increase LPS-induced pro-IL-1β production, but do not increase IL-1β secretion. A role for microtubules in the regulation of IL-1β production. J Immunol 154 8 (1995) 4113-4122
164. White C.M., Martin B.K., Lee L.F., Haskill J.S., and Ting J.P. Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells. Cancer Immunol Immunother 46 2 (1998) 104-112
165. Henkart P.A. ICE family proteases: mediators of all apoptotic cell death?. Immunity 4 3 (1996) 195-201
166. Cao Y., and Prescott S.M. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190 3 (2002) 279-286
167. Ruegg C., Zaric J., and Stupp R. Non-steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and reality. Annu Med 35 7 (2003) 476-487
168. Moos P.J., and Fitzpatrick F.A. Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci USA 95 7 (1998) 3896-3901
169. Subbaramaiah K., Hart J.C., Norton L., and Dannenberg A.J. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem 275 20 (2000) 14838-14845
170. Subbaramaiah K., Marmo T.P., Dixon D.A., and Dannenberg A.J. Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem 278 39 (2003) 37637-37647
171. Altorki N.K., Port J.L., Zhang F., et al. Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. Clin Cancer Res 11 11 (2005) 4191-4197
172. Choy H., and Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?. J Natl Cancer Inst 95 19 (2003) 1440-1452
173. Hida T., Kozaki K., Ito H., et al. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase-2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res 8 7 (2002) 2443-2447
174. Dandekar D.S., Lopez M., Carey R.I., and Lokeshwar B.L. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer 115 3 (2005) 484-492
175. Shaik M.S., Chatterjee A., Jackson T., and Singh M. Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int J Cancer 118 2 (2006) 396-404
176. Nugent F.W., Mertens W.C., Graziano S., et al. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial. Lung Cancer 48 2 (2005) 267-273
177. Gasparini G., Meo S., Comella G., et al. The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates. Cancer J 11 3 (2005) 209-216
178. Altorki N.K., Keresztes R.S., Port J.L., et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 21 14 (2003) 2645-2650
179. Datta S.R., Brunet A., and Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev 13 22 (1999) 2905-2927
180. Plas D.R., and Thompson C.B. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24 50 (2005) 7435-7442
181. Zimmermann S., and Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286 5445 (1999) 1741-1744
182. Cheng J.Q., Lindsley C.W., Cheng G.Z., Yang H., and Nicosia S.V. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24 50 (2005) 7482-7492
183. Mitsuuchi Y., Johnson S.W., Selvakumaran M., Williams S.J., Hamilton T.C., and Testa J.R. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res 60 19 (2000) 5390-5394
184. MacKeigan J.P., Taxman D.J., Hunter D., Earp III H.S., Graves L.M., and Ting J.P. Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of Taxol and mitogen-activated protein kinase inhibition. Clin Cancer Res 8 7 (2002) 2091-2099
185. Hu L., Hofmann J., Lu Y., Mills G.B., and Jaffe R.B. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in vitro and in vivo ovarian cancer models. Cancer Res 62 4 (2002) 1087-1092
186. Lin H.L., Lui W.Y., Liu T.Y., and Chi C.W. Reversal of Taxol resistance in hepatoma by cyclosporin A: involvement of the PI-3 kinase-AKT 1 pathway. Br J Cancer 88 6 (2003) 973-980
187. Shingu T., Yamada K., Hara N., et al. Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells. Cancer Res 63 14 (2003) 4044-4047
188. Asnaghi L., Bruno P., Priulla M., and Nicolin A. mTOR: a protein kinase switching between life and death. Pharmacol Res 50 6 (2004) 545-549
189. Le X.F., Hittelman W.N., Liu J., et al. Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene 22 4 (2003) 484-497
190. Koff A., and Polyak K. p27KIP1, an inhibitor of cyclin-dependent kinases. Prog Cell Cycle Res 1 (1995) 141-147
191. Dumont F.J., and Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci 58 5 (1996) 373-395
192. Calastretti A., Bevilacqua A., Ceriani C., et al. Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase. Oncogene 20 43 (2001) 6172-6180
193. VanderWeele D.J., Zhou R., and Rudin C.M. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol Cancer Ther 3 12 (2004) 1605-1613